Presenting features of infants with ALL treated on CCG 1953 and 1883
Variable and category* . | CCG 1953, no. of patients (%) . | CCG 1883, no. of patients (%) . | P . |
|---|---|---|---|
| Age | .224 | ||
| Less than 3 mo | 24 (20.9) | 21 (15.6) | |
| 3 to less than 6 mo | 37 (32.2) | 36 (26.7) | |
| At least 6 mo | 54 (47.0) | 78 (57.8) | |
| Race | .002 | ||
| White | 70 (62.5) | 96 (71.1) | |
| Hispanic | 34 (30.4) | 22 (16.3) | |
| Black | 0 (0.0) | 10 (7.4) | |
| Other/unknown | 8 (7.1) | 7 (5.2) | |
| Sex | .94 | ||
| Male | 54 (47.0) | 64 (47.4) | |
| Female | 61 (53.0) | 71 (52.6) | |
| WBC count | .58 | ||
| Less than 50 × 109/L | 37 (32.2) | 52 (38.5) | |
| 50 × 109/L to 199 × 109/L | 35 (30.4) | 37 (27.4) | |
| At least 200 × 109/L | 43 (37.4) | 46 (34.1) | |
| Liver | .91 | ||
| Normal | 25 (22.9) | 33 (24.4) | |
| Moderately enlarged | 70 (64.2) | 83 (61.5) | |
| Markedly enlarged | 14 (12.8) | 19 (14.1) | |
| Spleen | .66 | ||
| Normal | 22 (19.1) | 31 (23.0) | |
| Moderately enlarged | 65 (56.5) | 69 (51.1) | |
| Markedly enlarged | 28 (24.4) | 35 (25.9) | |
| CNS disease | .18 | ||
| Yes, CNS-3 | 18 (16.4) | 34 (25.4) | |
| Maybe, CNS-2 | 18 (16.4) | 24 (17.9) | |
| No, CNS-1 | 74 (63.7) | 76 (56.7) | |
| CD10 | .04 | ||
| CD10- | 82 (71.3) | 56 (57.7) | |
| CD10+ | 33 (28.7) | 41 (42.3) | |
| MLL/11q23 abnormality | .04 | ||
| Present | 79 (68.7) | 35 (53.0)† | |
| Absent | 36 (31.3) | 31 (47.0) |
Variable and category* . | CCG 1953, no. of patients (%) . | CCG 1883, no. of patients (%) . | P . |
|---|---|---|---|
| Age | .224 | ||
| Less than 3 mo | 24 (20.9) | 21 (15.6) | |
| 3 to less than 6 mo | 37 (32.2) | 36 (26.7) | |
| At least 6 mo | 54 (47.0) | 78 (57.8) | |
| Race | .002 | ||
| White | 70 (62.5) | 96 (71.1) | |
| Hispanic | 34 (30.4) | 22 (16.3) | |
| Black | 0 (0.0) | 10 (7.4) | |
| Other/unknown | 8 (7.1) | 7 (5.2) | |
| Sex | .94 | ||
| Male | 54 (47.0) | 64 (47.4) | |
| Female | 61 (53.0) | 71 (52.6) | |
| WBC count | .58 | ||
| Less than 50 × 109/L | 37 (32.2) | 52 (38.5) | |
| 50 × 109/L to 199 × 109/L | 35 (30.4) | 37 (27.4) | |
| At least 200 × 109/L | 43 (37.4) | 46 (34.1) | |
| Liver | .91 | ||
| Normal | 25 (22.9) | 33 (24.4) | |
| Moderately enlarged | 70 (64.2) | 83 (61.5) | |
| Markedly enlarged | 14 (12.8) | 19 (14.1) | |
| Spleen | .66 | ||
| Normal | 22 (19.1) | 31 (23.0) | |
| Moderately enlarged | 65 (56.5) | 69 (51.1) | |
| Markedly enlarged | 28 (24.4) | 35 (25.9) | |
| CNS disease | .18 | ||
| Yes, CNS-3 | 18 (16.4) | 34 (25.4) | |
| Maybe, CNS-2 | 18 (16.4) | 24 (17.9) | |
| No, CNS-1 | 74 (63.7) | 76 (56.7) | |
| CD10 | .04 | ||
| CD10- | 82 (71.3) | 56 (57.7) | |
| CD10+ | 33 (28.7) | 41 (42.3) | |
| MLL/11q23 abnormality | .04 | ||
| Present | 79 (68.7) | 35 (53.0)† | |
| Absent | 36 (31.3) | 31 (47.0) |
For the CCG 1953 study, N = 115; for the CCG 1883 study, N = 135.
For some variables, some data were not submitted for individual patients (liver size, race, CNS, CD10), so totals do not add up to 115.
11q23 info for 1883 is based solely on karyotypes accepted by central review. Information was not complete on all 135 patients. Percentages were calculated excluding patients for whom data were unknown.